Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNNI3K | Q59H18 | 19/20 | 0.69 |
| ▸ | EGFR | P00533 | 7/20 | 0.69 |
| ▸ | JAK2 | O60674 | 1/20 | 0.57 |
| ▸ | JAK3 | P52333 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL14323381 | 0.99 | TNNI3K (0.67) | TNNI3KEGFRJAK2JAK3 | |
| SCHEMBL12517453 | 0.94 | TNNI3K (0.69) | TNNI3KEGFR | |
| SCHEMBL2280214 | 0.92 | TNNI3K (0.64) | TNNI3KEGFR | |
| SCHEMBL2286544 | 0.91 | TNNI3K (0.70) | TNNI3KEGFR | |
| SCHEMBL12517875 | 0.86 | TNNI3K (0.70) | TNNI3KEGFR | |
| SCHEMBL12516327 | 0.86 | TNNI3K (0.56) | TNNI3KEGFR | |
| SCHEMBL12516272 | 0.85 | TNNI3K (0.62) | TNNI3KEGFR | |
| SCHEMBL12517466 | 0.84 | TNNI3K (0.73) | TNNI3KEGFR | |
| SCHEMBL2273957 | 0.83 | TNNI3K (0.89) | TNNI3KEGFR | |
| SCHEMBL12517819 | 0.83 | TNNI3K (0.63) | TNNI3KEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120329784-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC | 2012-12-27 | — | — | US | claimed |
| US-20120329784-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC | 2012-12-27 | — | — | US | disclosed |
| US-20120329784-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC | 2012-12-27 | — | — | US | disclosed |
| WO-2011088027-A1 | COMPOUNDS AND METHODS | GLAXOSMITHKLINE LLC (US) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329784-A1 | COMPOUNDS AND METHODS | RB1, DHFR, NQO1 | TNNI3K 2596/4885EGFR 888/4885JAK2 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.